TABLE 2.

Potencies of anti-tuberculosis agents against M. tuberculosis^a

Antibioticb	MIC99 (μg/ml)c	MPC (μg/ml)d	Dose (mg)e	Cmaxf	MPC/ Cmax	Reference for Cmax
Rifampin	0.02	>80	600	9.5	>8	2
Streptomycin	0.2	>320	1000	34	>9	1, 4
Isoniazid	0.06	20	250	7.6	2.6	2
Capreomycin	2.0	160	1,000	33	4.8	4
Kanamycin	1.5	>800	500	21	>38	5
Cycloserine	14	70	750	35	2	23
Fluoroquinolones
Ciprofloxacin	0.15	8.0	750	4.4	1.8	9
Moxifloxacin	0.037	2.5	400	4.5	0.55	17
PD135432g	0.03	1.5	300	3.7	0.41	15
Sparfloxacin	0.075	2.5	200	1.4	1.8	14
PD161148	0.07	1.5		NAh

^aExperiments were performed with isolate TN6515. 

^bUnless indicated otherwise the source of all compounds was Sigma Biochemicals. The exceptions were as follows: ciprofloxacin, Miles Laboratories; moxifloxacin, Bayer AG; PD135432, Parke-Davis; sparfloxacin, Parke-Davis; and PD161148, Parke-Davis. 

^cMIC₉₉, MIC at which 99% of isolates are inhibited. 

^dThe MPC was determined as described in footnote a of Table 1. The MPC of each compound was determined twice, with results similar to those shown obtained each time. 

^eThe dose recommended by the manufacturer. For determination of the maximum concentration of drug in serum, streptomycin, capreomycin, and kanamycin were administered as single, intramuscular doses; all other compounds except ciprofloxacin and PD135432 were administered as oral doses once daily; ciprofloxacin and PD135432 were delivered twice daily. The initial dose of sparfloxacin was 400 mg. During treatment of tuberculosis, kanamycin is administered twice daily. 

^fC_max, maximum concentration of drug in serum. All are steady-state determinations except for those for streptomycin, capreomycin, and kanamycin, which were single-dose determinations. 

^gStructure identical to that of gatifloxacin. 

^hNA, not available.